Cantor Fitzgerald reiterates a Buy rating and $2.00 price target on StemCells (NASDAQ: STEM) ahead of GA data that is anticipated to be Presented this week. Analyst Caroline Corner expects positive results, based on interim data.

Corner commented, "We anticipate that data will be presented this week at the International Society for Stem Cell Research (ISSCR) in Stockholm from StemCells's Phase I/II clinical trial in dry age-related macular degeneration (dryAMD)/ Geographic Atrophy (GA). Based on interim data we expect positive results, which we believe should increase confidence regarding a positive outcome for the company's Phase III GA trial, Radiant. We maintain our BUY rating and $2 PT."

For an analyst ratings summary and ratings history on StemCells click here. For more ratings news on StemCells click here.

Shares of StemCells closed at $0.70 yesterday.